ERBB2 and breast cancer: Chemotherapy, combined with dual anti-HER2 therapies, have been used as neoadjuvant treatment in HER2+ BC patients to improve the pathological complete response (pCR) rate7 which is predictive for more favorable long-term outcome8,9.